NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka recently discussed the company’s plans regarding technology licensing contracts in an audio interview. An article further discussing the company reads: “LXRP is a British Columbia, Canada-based bioscience company that is a drug delivery platform innovator. The company has developed its patented DehydraTECH™ delivery technology platform, which it out-licenses to promote healthier ingestion methods and lower overall dosing. …Bunka said that LXRP believes that 6-12 more licensing contracts will be signed this year, both generating more revenue for the company and building greater shareholder value. “We’ve only just graduated from the demonstration phase,” he explained in the interview.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer